Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13911759 | 0.87 | NPBWR1 (0.50) | DPP4NPBWR1MAPT | |
| SCHEMBL4059657 | 0.85 | NPBWR1 (0.51) | DPP4NPBWR1MAPT | |
| SCHEMBL5842838 | 0.84 | DPP4 (0.60) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4068768 | 0.76 | DPP4 (1.00) | DPP4CHRM1 | |
| SCHEMBL5354911 | 0.76 | DPP4 (0.53) | DPP4CHRM1NPBWR1 | |
| Hydrochloric Acid SCHEMBL5842832 | 0.76 | DPP4 (0.98) | DPP4CHRM1 | |
| SCHEMBL5354904 | 0.74 | DPP4 (0.51) | DPP4CHRM1NPBWR1 | |
| SCHEMBL5841351 | 0.73 | DPP4 (0.76) | DPP4CHRM1 | |
| SCHEMBL5373179 | 0.73 | DPP4 (0.66) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4248350 | 0.72 | DPP4 (0.53) | DPP4CHRM1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 552/4885NPBWR1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.